Alnylam Pharmaceuticals, Inc (ALNY) shares are up almost 8% pre-market after the company reported positive results from a trial of its ALN-HBV for the treatment of hepatitis B virus in chimpanzees.
“Alnylam’s new ALN-HBV program is a mature, pre-clinical asset acquired through the company’s acquisition of Sirna from Merck. We are very encouraged by the data we are presenting for the first time today, which we believe constitute the most robust proof-of-concept pre-clinical data to date with an RNAi therapeutic for the treatment of HBV,” said company vice president Laura Sepp-Lorenzino.
The stock recently traded at $58.50 and has moved in a 52-week range of $25.57 – $112.57.
Latest posts by Anne-Marie Jackson (see all)
- SF Hospital Slaps New Parents with $19K Bill for Baby Treatment - Mar 17, 2019
- Furious Trump Blasts Harley-Davidson for Moving Production Overseas - Mar 17, 2019
- Warning! MRI Machines Could Poison You - Mar 17, 2019